. 2008 Apr 28;52(7):2313–2323. doi: 10.1128/AAC.01649-07

TABLE 3.

Antibacterial activities of CBR-2092 against isogenic Staphylococcus aureus strains bearing combinations of rifamycin or quinolone resistance mutations

Test agent (condition)^a	MIC (μg/ml)
Test agent (condition)^a	CB190 wild type	CB811 gyrA^S84L	CB808 parC^S80F	CB814 gyrA^S84LparC^S80F	CB370 rpoB^H481Y	CB812 rpoB^H481YgyrA^S84L	CB809 rpoB^H481YparC^S80F	CB815 rpoB^H481YgyrA^S84LparC^S80F
CBR-2092 (agar)	0.008	0.008	0.008	0.008	0.06	0.12	0.06	0.25
CBR-2092	0.015	0.015	0.015	0.015	0.12	0.50	0.25	2
Rifampin	0.008	0.008	0.008	0.008	>250	>250	>250	>250
Ciprofloxacin	0.25	0.25	2	16	0.25	0.25	2	16
Levofloxacin	0.25	0.25	1	8	0.25	0.25	1	8
Gatifloxacin	0.06	0.12	0.25	8	0.06	0.12	0.25	8
ABT-719	0.015	0.03	0.03	0.50	0.015	0.03	0.03	0.25

MICs were determined by the broth microdilution method in the presence of 0.002% (vol/vol) P-80 unless otherwise indicated.